nodes	percent_of_prediction	percent_of_DWPC	metapath
Mianserin—CYP1A2—Imiquimod—skin cancer	0.132	0.224	CbGbCtD
Mianserin—CYP1A2—Vemurafenib—skin cancer	0.0722	0.123	CbGbCtD
Mianserin—CYP3A4—Imiquimod—skin cancer	0.069	0.117	CbGbCtD
Mianserin—CYP3A4—Temozolomide—skin cancer	0.069	0.117	CbGbCtD
Mianserin—CYP2D6—Vemurafenib—skin cancer	0.0595	0.101	CbGbCtD
Mianserin—CYP1A2—Dacarbazine—skin cancer	0.0553	0.0941	CbGbCtD
Mianserin—CYP3A4—Vismodegib—skin cancer	0.0479	0.0814	CbGbCtD
Mianserin—CYP3A4—Vemurafenib—skin cancer	0.0378	0.0643	CbGbCtD
Mianserin—CYP1A2—Fluorouracil—skin cancer	0.0324	0.0552	CbGbCtD
Mianserin—CYP3A4—Docetaxel—skin cancer	0.013	0.0221	CbGbCtD
Mianserin—HRH1—nose—skin cancer	0.00715	0.0819	CbGeAlD
Mianserin—Hepatic enzyme increased—Vismodegib—skin cancer	0.0067	0.027	CcSEcCtD
Mianserin—Electrocardiogram QT prolonged—Vemurafenib—skin cancer	0.0061	0.0246	CcSEcCtD
Mianserin—Breast disorder—Vismodegib—skin cancer	0.00416	0.0168	CcSEcCtD
Mianserin—Hepatic enzyme increased—Imiquimod—skin cancer	0.00353	0.0143	CcSEcCtD
Mianserin—SLC6A3—nerve—skin cancer	0.00353	0.0404	CbGeAlD
Mianserin—Connective tissue disorder—Vismodegib—skin cancer	0.00313	0.0126	CcSEcCtD
Mianserin—Arthritis—Vemurafenib—skin cancer	0.00292	0.0118	CcSEcCtD
Mianserin—SLC6A2—nerve—skin cancer	0.00285	0.0326	CbGeAlD
Mianserin—HTR2A—hindlimb—skin cancer	0.00281	0.0323	CbGeAlD
Mianserin—Hepatic function abnormal—Imiquimod—skin cancer	0.00277	0.0112	CcSEcCtD
Mianserin—HTR7—nerve—skin cancer	0.00274	0.0314	CbGeAlD
Mianserin—HTR1D—blood vessel—skin cancer	0.0027	0.031	CbGeAlD
Mianserin—Nasal congestion—Imiquimod—skin cancer	0.00266	0.0107	CcSEcCtD
Mianserin—DRD2—nerve—skin cancer	0.00259	0.0297	CbGeAlD
Mianserin—Arthritis—Imiquimod—skin cancer	0.00249	0.0101	CcSEcCtD
Mianserin—Cardiac failure—Imiquimod—skin cancer	0.00248	0.01	CcSEcCtD
Mianserin—Lethargy—Imiquimod—skin cancer	0.00247	0.00998	CcSEcCtD
Mianserin—HTR2A—appendage—skin cancer	0.00241	0.0277	CbGeAlD
Mianserin—Myalgia—Vismodegib—skin cancer	0.00236	0.00952	CcSEcCtD
Mianserin—Arthralgia—Vismodegib—skin cancer	0.00236	0.00952	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00234	0.00946	CcSEcCtD
Mianserin—HTR7—endothelium—skin cancer	0.00234	0.0268	CbGeAlD
Mianserin—Nervous system disorder—Vismodegib—skin cancer	0.00222	0.00895	CcSEcCtD
Mianserin—Skin disorder—Vismodegib—skin cancer	0.0022	0.00887	CcSEcCtD
Mianserin—Breast disorder—Imiquimod—skin cancer	0.00219	0.00884	CcSEcCtD
Mianserin—HTR7—blood vessel—skin cancer	0.00215	0.0247	CbGeAlD
Mianserin—Hepatic enzyme increased—Temozolomide—skin cancer	0.00211	0.00854	CcSEcCtD
Mianserin—HTR1F—head—skin cancer	0.00206	0.0236	CbGeAlD
Mianserin—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00206	0.00832	CcSEcCtD
Mianserin—Pancytopenia—Imiquimod—skin cancer	0.00199	0.00803	CcSEcCtD
Mianserin—HRH2—skin of body—skin cancer	0.00196	0.0225	CbGeAlD
Mianserin—Gastrointestinal disorder—Vismodegib—skin cancer	0.00195	0.00788	CcSEcCtD
Mianserin—Fatigue—Vismodegib—skin cancer	0.00195	0.00787	CcSEcCtD
Mianserin—Constipation—Vismodegib—skin cancer	0.00193	0.00781	CcSEcCtD
Mianserin—Connective tissue disorder—Vemurafenib—skin cancer	0.00193	0.0078	CcSEcCtD
Mianserin—Erectile dysfunction—Imiquimod—skin cancer	0.00193	0.00779	CcSEcCtD
Mianserin—Eye disorder—Vemurafenib—skin cancer	0.00184	0.00742	CcSEcCtD
Mianserin—Cardiac disorder—Vemurafenib—skin cancer	0.00182	0.00737	CcSEcCtD
Mianserin—Angiopathy—Vemurafenib—skin cancer	0.00178	0.0072	CcSEcCtD
Mianserin—Mediastinal disorder—Vemurafenib—skin cancer	0.00177	0.00715	CcSEcCtD
Mianserin—Arthritis—Bleomycin—skin cancer	0.00177	0.00715	CcSEcCtD
Mianserin—Hepatobiliary disease—Imiquimod—skin cancer	0.00177	0.00713	CcSEcCtD
Mianserin—HTR2A—nerve—skin cancer	0.00171	0.0196	CbGeAlD
Mianserin—Connective tissue disorder—Imiquimod—skin cancer	0.00165	0.00665	CcSEcCtD
Mianserin—Lethargy—Dactinomycin—skin cancer	0.00164	0.00662	CcSEcCtD
Mianserin—Asthenia—Vismodegib—skin cancer	0.00162	0.00655	CcSEcCtD
Mianserin—Pruritus—Vismodegib—skin cancer	0.0016	0.00646	CcSEcCtD
Mianserin—Nasal congestion—Temozolomide—skin cancer	0.00159	0.00644	CcSEcCtD
Mianserin—Eye disorder—Imiquimod—skin cancer	0.00157	0.00633	CcSEcCtD
Mianserin—Tinnitus—Imiquimod—skin cancer	0.00156	0.00631	CcSEcCtD
Mianserin—OPRK1—female reproductive system—skin cancer	0.00155	0.0178	CbGeAlD
Mianserin—HTR7—neck—skin cancer	0.00154	0.0177	CbGeAlD
Mianserin—Angiopathy—Imiquimod—skin cancer	0.00152	0.00614	CcSEcCtD
Mianserin—Mediastinal disorder—Imiquimod—skin cancer	0.00151	0.0061	CcSEcCtD
Mianserin—Mental disorder—Imiquimod—skin cancer	0.00147	0.00593	CcSEcCtD
Mianserin—Myalgia—Vemurafenib—skin cancer	0.00146	0.00588	CcSEcCtD
Mianserin—Arthralgia—Vemurafenib—skin cancer	0.00146	0.00588	CcSEcCtD
Mianserin—HTR2A—endothelium—skin cancer	0.00146	0.0167	CbGeAlD
Mianserin—DRD3—head—skin cancer	0.00145	0.0167	CbGeAlD
Mianserin—Diplopia—Temozolomide—skin cancer	0.00145	0.00586	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00145	0.00584	CcSEcCtD
Mianserin—ADRA2C—nipple—skin cancer	0.00143	0.0164	CbGeAlD
Mianserin—Rash—Vismodegib—skin cancer	0.00143	0.00576	CcSEcCtD
Mianserin—Dermatitis—Vismodegib—skin cancer	0.00142	0.00575	CcSEcCtD
Mianserin—Pancytopenia—Bleomycin—skin cancer	0.00141	0.00571	CcSEcCtD
Mianserin—HTR6—head—skin cancer	0.0014	0.016	CbGeAlD
Mianserin—HTR1D—connective tissue—skin cancer	0.00139	0.0159	CbGeAlD
Mianserin—Cardiac failure—Fluorouracil—skin cancer	0.00137	0.00554	CcSEcCtD
Mianserin—Nervous system disorder—Vemurafenib—skin cancer	0.00137	0.00553	CcSEcCtD
Mianserin—Lethargy—Fluorouracil—skin cancer	0.00137	0.00551	CcSEcCtD
Mianserin—Skin disorder—Vemurafenib—skin cancer	0.00136	0.00548	CcSEcCtD
Mianserin—HTR2A—blood vessel—skin cancer	0.00134	0.0154	CbGeAlD
Mianserin—Agitation—Imiquimod—skin cancer	0.00134	0.00541	CcSEcCtD
Mianserin—Pancytopenia—Dactinomycin—skin cancer	0.00132	0.00532	CcSEcCtD
Mianserin—Breast disorder—Temozolomide—skin cancer	0.00131	0.0053	CcSEcCtD
Mianserin—Syncope—Imiquimod—skin cancer	0.00131	0.00528	CcSEcCtD
Mianserin—Hypotension—Vemurafenib—skin cancer	0.0013	0.00527	CcSEcCtD
Mianserin—Neutropenia—Dactinomycin—skin cancer	0.0013	0.00524	CcSEcCtD
Mianserin—OPRK1—head—skin cancer	0.0013	0.0149	CbGeAlD
Mianserin—Loss of consciousness—Imiquimod—skin cancer	0.00128	0.00518	CcSEcCtD
Mianserin—HRH2—head—skin cancer	0.00128	0.0147	CbGeAlD
Mianserin—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00127	0.00514	CcSEcCtD
Mianserin—Cardiac arrest—Fluorouracil—skin cancer	0.00127	0.00514	CcSEcCtD
Mianserin—Convulsion—Imiquimod—skin cancer	0.00126	0.00511	CcSEcCtD
Mianserin—Hypertension—Imiquimod—skin cancer	0.00126	0.00509	CcSEcCtD
Mianserin—Myalgia—Imiquimod—skin cancer	0.00124	0.00502	CcSEcCtD
Mianserin—Arthralgia—Imiquimod—skin cancer	0.00124	0.00502	CcSEcCtD
Mianserin—CYP1A2—nipple—skin cancer	0.00124	0.0142	CbGeAlD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00123	0.00498	CcSEcCtD
Mianserin—Dry mouth—Imiquimod—skin cancer	0.00122	0.00491	CcSEcCtD
Mianserin—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00121	0.00487	CcSEcCtD
Mianserin—Fatigue—Vemurafenib—skin cancer	0.0012	0.00486	CcSEcCtD
Mianserin—Constipation—Vemurafenib—skin cancer	0.00119	0.00482	CcSEcCtD
Mianserin—Pancytopenia—Temozolomide—skin cancer	0.00119	0.00481	CcSEcCtD
Mianserin—Oedema—Imiquimod—skin cancer	0.00119	0.00481	CcSEcCtD
Mianserin—Neutropenia—Temozolomide—skin cancer	0.00117	0.00474	CcSEcCtD
Mianserin—Shock—Imiquimod—skin cancer	0.00117	0.00473	CcSEcCtD
Mianserin—Nervous system disorder—Imiquimod—skin cancer	0.00117	0.00472	CcSEcCtD
Mianserin—HTR2B—skin of body—skin cancer	0.00116	0.0134	CbGeAlD
Mianserin—HRH1—nipple—skin cancer	0.00116	0.0133	CbGeAlD
Mianserin—Tachycardia—Imiquimod—skin cancer	0.00116	0.00469	CcSEcCtD
Mianserin—Skin disorder—Imiquimod—skin cancer	0.00116	0.00467	CcSEcCtD
Mianserin—Erectile dysfunction—Temozolomide—skin cancer	0.00116	0.00467	CcSEcCtD
Mianserin—Agranulocytosis—Dactinomycin—skin cancer	0.00115	0.00466	CcSEcCtD
Mianserin—Weight increased—Temozolomide—skin cancer	0.00114	0.00461	CcSEcCtD
Mianserin—ADRA2A—nipple—skin cancer	0.00114	0.0131	CbGeAlD
Mianserin—Hepatitis—Dactinomycin—skin cancer	0.00111	0.00448	CcSEcCtD
Mianserin—HTR7—connective tissue—skin cancer	0.0011	0.0127	CbGeAlD
Mianserin—Pancytopenia—Fluorouracil—skin cancer	0.0011	0.00443	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00109	0.00438	CcSEcCtD
Mianserin—Paraesthesia—Imiquimod—skin cancer	0.00107	0.00432	CcSEcCtD
Mianserin—Somnolence—Imiquimod—skin cancer	0.00106	0.00428	CcSEcCtD
Mianserin—Hepatobiliary disease—Temozolomide—skin cancer	0.00106	0.00427	CcSEcCtD
Mianserin—HTR7—epithelium—skin cancer	0.00105	0.012	CbGeAlD
Mianserin—Gastrointestinal disorder—Imiquimod—skin cancer	0.00103	0.00415	CcSEcCtD
Mianserin—Fatigue—Imiquimod—skin cancer	0.00103	0.00415	CcSEcCtD
Mianserin—Hepatitis—Temozolomide—skin cancer	0.001	0.00406	CcSEcCtD
Mianserin—Asthenia—Vemurafenib—skin cancer	0.001	0.00405	CcSEcCtD
Mianserin—Cardiac failure—Docetaxel—skin cancer	0.00099	0.004	CcSEcCtD
Mianserin—Pruritus—Vemurafenib—skin cancer	0.000988	0.00399	CcSEcCtD
Mianserin—Connective tissue disorder—Temozolomide—skin cancer	0.000987	0.00399	CcSEcCtD
Mianserin—Lethargy—Docetaxel—skin cancer	0.000985	0.00398	CcSEcCtD
Mianserin—Feeling abnormal—Imiquimod—skin cancer	0.000981	0.00396	CcSEcCtD
Mianserin—HTR1D—female reproductive system—skin cancer	0.000978	0.0112	CbGeAlD
Mianserin—HTR2C—female reproductive system—skin cancer	0.000968	0.0111	CbGeAlD
Mianserin—Agranulocytosis—Fluorouracil—skin cancer	0.000962	0.00389	CcSEcCtD
Mianserin—HTR2A—neck—skin cancer	0.000961	0.011	CbGeAlD
Mianserin—Anaemia—Bleomycin—skin cancer	0.000958	0.00387	CcSEcCtD
Mianserin—Eye disorder—Temozolomide—skin cancer	0.000939	0.00379	CcSEcCtD
Mianserin—Tinnitus—Temozolomide—skin cancer	0.000937	0.00378	CcSEcCtD
Mianserin—Cardiac disorder—Temozolomide—skin cancer	0.000932	0.00376	CcSEcCtD
Mianserin—Leukopenia—Bleomycin—skin cancer	0.000928	0.00375	CcSEcCtD
Mianserin—Dizziness—Vemurafenib—skin cancer	0.000923	0.00373	CcSEcCtD
Mianserin—SLC6A4—female reproductive system—skin cancer	0.000918	0.0105	CbGeAlD
Mianserin—Angiopathy—Temozolomide—skin cancer	0.000911	0.00368	CcSEcCtD
Mianserin—HTR2B—female reproductive system—skin cancer	0.00091	0.0104	CbGeAlD
Mianserin—Mediastinal disorder—Temozolomide—skin cancer	0.000905	0.00366	CcSEcCtD
Mianserin—HRH2—lymph node—skin cancer	0.000896	0.0103	CbGeAlD
Mianserin—Anaemia—Dactinomycin—skin cancer	0.000894	0.00361	CcSEcCtD
Mianserin—Myalgia—Bleomycin—skin cancer	0.000883	0.00356	CcSEcCtD
Mianserin—Rash—Vemurafenib—skin cancer	0.000881	0.00356	CcSEcCtD
Mianserin—Mental disorder—Temozolomide—skin cancer	0.00088	0.00355	CcSEcCtD
Mianserin—Dermatitis—Vemurafenib—skin cancer	0.00088	0.00355	CcSEcCtD
Mianserin—Headache—Vemurafenib—skin cancer	0.000875	0.00353	CcSEcCtD
Mianserin—Breast disorder—Docetaxel—skin cancer	0.000873	0.00352	CcSEcCtD
Mianserin—Leukopenia—Dactinomycin—skin cancer	0.000865	0.00349	CcSEcCtD
Mianserin—Asthenia—Imiquimod—skin cancer	0.000854	0.00345	CcSEcCtD
Mianserin—Confusional state—Bleomycin—skin cancer	0.000853	0.00344	CcSEcCtD
Mianserin—Oedema—Bleomycin—skin cancer	0.000846	0.00342	CcSEcCtD
Mianserin—Pruritus—Imiquimod—skin cancer	0.000843	0.0034	CcSEcCtD
Mianserin—SLC6A3—head—skin cancer	0.000837	0.00959	CbGeAlD
Mianserin—ADRA2C—mammalian vulva—skin cancer	0.000836	0.00958	CbGeAlD
Mianserin—Thrombocytopenia—Bleomycin—skin cancer	0.000828	0.00335	CcSEcCtD
Mianserin—HRH1—connective tissue—skin cancer	0.000825	0.00945	CbGeAlD
Mianserin—Myalgia—Dactinomycin—skin cancer	0.000823	0.00332	CcSEcCtD
Mianserin—Tremor—Temozolomide—skin cancer	0.000819	0.00331	CcSEcCtD
Mianserin—HTR1D—head—skin cancer	0.000817	0.00937	CbGeAlD
Mianserin—ADRA2A—connective tissue—skin cancer	0.00081	0.00929	CbGeAlD
Mianserin—HTR2C—head—skin cancer	0.000809	0.00927	CbGeAlD
Mianserin—Anaemia—Temozolomide—skin cancer	0.000808	0.00326	CcSEcCtD
Mianserin—SLC6A2—female reproductive system—skin cancer	0.000808	0.00927	CbGeAlD
Mianserin—Agitation—Temozolomide—skin cancer	0.000804	0.00325	CcSEcCtD
Mianserin—Pancytopenia—Docetaxel—skin cancer	0.000793	0.0032	CcSEcCtD
Mianserin—Hypotension—Bleomycin—skin cancer	0.000791	0.00319	CcSEcCtD
Mianserin—Oedema—Dactinomycin—skin cancer	0.000789	0.00319	CcSEcCtD
Mianserin—Dizziness—Imiquimod—skin cancer	0.000788	0.00318	CcSEcCtD
Mianserin—Vertigo—Temozolomide—skin cancer	0.000786	0.00317	CcSEcCtD
Mianserin—HRH1—epithelium—skin cancer	0.000783	0.00898	CbGeAlD
Mianserin—Leukopenia—Temozolomide—skin cancer	0.000783	0.00316	CcSEcCtD
Mianserin—Neutropenia—Docetaxel—skin cancer	0.00078	0.00315	CcSEcCtD
Mianserin—HTR7—female reproductive system—skin cancer	0.000779	0.00893	CbGeAlD
Mianserin—Thrombocytopenia—Dactinomycin—skin cancer	0.000773	0.00312	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000771	0.00311	CcSEcCtD
Mianserin—SLC6A4—head—skin cancer	0.000767	0.00879	CbGeAlD
Mianserin—CYP2B6—skin of body—skin cancer	0.000762	0.00874	CbGeAlD
Mianserin—HTR2B—head—skin cancer	0.00076	0.00871	CbGeAlD
Mianserin—Paraesthesia—Bleomycin—skin cancer	0.00076	0.00307	CcSEcCtD
Mianserin—Weight increased—Docetaxel—skin cancer	0.00076	0.00307	CcSEcCtD
Mianserin—Convulsion—Temozolomide—skin cancer	0.000758	0.00306	CcSEcCtD
Mianserin—Hypertension—Temozolomide—skin cancer	0.000755	0.00305	CcSEcCtD
Mianserin—Rash—Imiquimod—skin cancer	0.000751	0.00303	CcSEcCtD
Mianserin—Dermatitis—Imiquimod—skin cancer	0.00075	0.00303	CcSEcCtD
Mianserin—Headache—Imiquimod—skin cancer	0.000746	0.00301	CcSEcCtD
Mianserin—Anaemia—Fluorouracil—skin cancer	0.000745	0.00301	CcSEcCtD
Mianserin—Myalgia—Temozolomide—skin cancer	0.000745	0.00301	CcSEcCtD
Mianserin—Arthralgia—Temozolomide—skin cancer	0.000745	0.00301	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000739	0.00299	CcSEcCtD
Mianserin—Dry mouth—Temozolomide—skin cancer	0.000728	0.00294	CcSEcCtD
Mianserin—Jaundice—Docetaxel—skin cancer	0.000725	0.00293	CcSEcCtD
Mianserin—Leukopenia—Fluorouracil—skin cancer	0.000721	0.00291	CcSEcCtD
Mianserin—Confusional state—Temozolomide—skin cancer	0.00072	0.00291	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000719	0.0029	CcSEcCtD
Mianserin—Oedema—Temozolomide—skin cancer	0.000714	0.00288	CcSEcCtD
Mianserin—Hepatobiliary disease—Docetaxel—skin cancer	0.000704	0.00284	CcSEcCtD
Mianserin—Nervous system disorder—Temozolomide—skin cancer	0.0007	0.00283	CcSEcCtD
Mianserin—Thrombocytopenia—Temozolomide—skin cancer	0.000699	0.00282	CcSEcCtD
Mianserin—Convulsion—Fluorouracil—skin cancer	0.000698	0.00282	CcSEcCtD
Mianserin—Feeling abnormal—Bleomycin—skin cancer	0.000697	0.00282	CcSEcCtD
Mianserin—Agranulocytosis—Docetaxel—skin cancer	0.000694	0.0028	CcSEcCtD
Mianserin—Skin disorder—Temozolomide—skin cancer	0.000693	0.0028	CcSEcCtD
Mianserin—HTR2A—connective tissue—skin cancer	0.000689	0.0079	CbGeAlD
Mianserin—Myalgia—Fluorouracil—skin cancer	0.000686	0.00277	CcSEcCtD
Mianserin—HTR1A—head—skin cancer	0.000681	0.00781	CbGeAlD
Mianserin—Fatigue—Dactinomycin—skin cancer	0.00068	0.00275	CcSEcCtD
Mianserin—HRH1—mammalian vulva—skin cancer	0.000679	0.00779	CbGeAlD
Mianserin—SLC6A2—head—skin cancer	0.000675	0.00774	CbGeAlD
Mianserin—Hepatitis—Docetaxel—skin cancer	0.000668	0.0027	CcSEcCtD
Mianserin—ADRA2A—mammalian vulva—skin cancer	0.000667	0.00765	CbGeAlD
Mianserin—Confusional state—Fluorouracil—skin cancer	0.000663	0.00268	CcSEcCtD
Mianserin—Oedema—Fluorouracil—skin cancer	0.000658	0.00266	CcSEcCtD
Mianserin—Connective tissue disorder—Docetaxel—skin cancer	0.000656	0.00265	CcSEcCtD
Mianserin—HTR2A—epithelium—skin cancer	0.000654	0.0075	CbGeAlD
Mianserin—HTR7—head—skin cancer	0.000651	0.00746	CbGeAlD
Mianserin—Feeling abnormal—Dactinomycin—skin cancer	0.00065	0.00263	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00065	0.00263	CcSEcCtD
Mianserin—Nervous system disorder—Fluorouracil—skin cancer	0.000645	0.0026	CcSEcCtD
Mianserin—Thrombocytopenia—Fluorouracil—skin cancer	0.000644	0.0026	CcSEcCtD
Mianserin—Tachycardia—Fluorouracil—skin cancer	0.000642	0.00259	CcSEcCtD
Mianserin—Paraesthesia—Temozolomide—skin cancer	0.000641	0.00259	CcSEcCtD
Mianserin—Somnolence—Temozolomide—skin cancer	0.000634	0.00256	CcSEcCtD
Mianserin—Eye disorder—Docetaxel—skin cancer	0.000624	0.00252	CcSEcCtD
Mianserin—Cardiac disorder—Docetaxel—skin cancer	0.00062	0.0025	CcSEcCtD
Mianserin—CYP2B6—lymphoid tissue—skin cancer	0.000617	0.00708	CbGeAlD
Mianserin—Gastrointestinal disorder—Temozolomide—skin cancer	0.000616	0.00249	CcSEcCtD
Mianserin—Fatigue—Temozolomide—skin cancer	0.000615	0.00248	CcSEcCtD
Mianserin—DRD2—head—skin cancer	0.000615	0.00705	CbGeAlD
Mianserin—Hypotension—Fluorouracil—skin cancer	0.000614	0.00248	CcSEcCtD
Mianserin—Constipation—Temozolomide—skin cancer	0.00061	0.00246	CcSEcCtD
Mianserin—Asthenia—Bleomycin—skin cancer	0.000607	0.00245	CcSEcCtD
Mianserin—Angiopathy—Docetaxel—skin cancer	0.000606	0.00245	CcSEcCtD
Mianserin—Mediastinal disorder—Docetaxel—skin cancer	0.000602	0.00243	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000599	0.00242	CcSEcCtD
Mianserin—Pruritus—Bleomycin—skin cancer	0.000599	0.00242	CcSEcCtD
Mianserin—ADRA2C—head—skin cancer	0.000598	0.00686	CbGeAlD
Mianserin—CYP2B6—female reproductive system—skin cancer	0.000596	0.00683	CbGeAlD
Mianserin—Paraesthesia—Fluorouracil—skin cancer	0.00059	0.00238	CcSEcCtD
Mianserin—Feeling abnormal—Temozolomide—skin cancer	0.000588	0.00237	CcSEcCtD
Mianserin—Mental disorder—Docetaxel—skin cancer	0.000585	0.00236	CcSEcCtD
Mianserin—Somnolence—Fluorouracil—skin cancer	0.000585	0.00236	CcSEcCtD
Mianserin—HRH1—female reproductive system—skin cancer	0.000582	0.00667	CbGeAlD
Mianserin—ADRA2A—female reproductive system—skin cancer	0.000571	0.00655	CbGeAlD
Mianserin—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000568	0.00229	CcSEcCtD
Mianserin—Asthenia—Dactinomycin—skin cancer	0.000566	0.00229	CcSEcCtD
Mianserin—Feeling abnormal—Fluorouracil—skin cancer	0.000542	0.00219	CcSEcCtD
Mianserin—Anaemia—Docetaxel—skin cancer	0.000538	0.00217	CcSEcCtD
Mianserin—Rash—Bleomycin—skin cancer	0.000533	0.00215	CcSEcCtD
Mianserin—Dermatitis—Bleomycin—skin cancer	0.000533	0.00215	CcSEcCtD
Mianserin—HTR2B—lymph node—skin cancer	0.000532	0.0061	CbGeAlD
Mianserin—Syncope—Docetaxel—skin cancer	0.000522	0.00211	CcSEcCtD
Mianserin—Leukopenia—Docetaxel—skin cancer	0.000521	0.0021	CcSEcCtD
Mianserin—Asthenia—Temozolomide—skin cancer	0.000512	0.00207	CcSEcCtD
Mianserin—Loss of consciousness—Docetaxel—skin cancer	0.000511	0.00206	CcSEcCtD
Mianserin—Pruritus—Temozolomide—skin cancer	0.000505	0.00204	CcSEcCtD
Mianserin—Convulsion—Docetaxel—skin cancer	0.000504	0.00203	CcSEcCtD
Mianserin—Hypertension—Docetaxel—skin cancer	0.000502	0.00203	CcSEcCtD
Mianserin—Rash—Dactinomycin—skin cancer	0.000498	0.00201	CcSEcCtD
Mianserin—CYP2B6—head—skin cancer	0.000498	0.0057	CbGeAlD
Mianserin—Arthralgia—Docetaxel—skin cancer	0.000495	0.002	CcSEcCtD
Mianserin—Myalgia—Docetaxel—skin cancer	0.000495	0.002	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000492	0.00199	CcSEcCtD
Mianserin—HRH1—head—skin cancer	0.000486	0.00557	CbGeAlD
Mianserin—HTR2A—female reproductive system—skin cancer	0.000486	0.00557	CbGeAlD
Mianserin—Dry mouth—Docetaxel—skin cancer	0.000484	0.00196	CcSEcCtD
Mianserin—Confusional state—Docetaxel—skin cancer	0.000479	0.00193	CcSEcCtD
Mianserin—ADRA2A—head—skin cancer	0.000477	0.00547	CbGeAlD
Mianserin—Oedema—Docetaxel—skin cancer	0.000475	0.00192	CcSEcCtD
Mianserin—SLC6A2—lymph node—skin cancer	0.000473	0.00542	CbGeAlD
Mianserin—Dizziness—Temozolomide—skin cancer	0.000472	0.00191	CcSEcCtD
Mianserin—Shock—Docetaxel—skin cancer	0.000467	0.00189	CcSEcCtD
Mianserin—Nervous system disorder—Docetaxel—skin cancer	0.000465	0.00188	CcSEcCtD
Mianserin—Pruritus—Fluorouracil—skin cancer	0.000465	0.00188	CcSEcCtD
Mianserin—Thrombocytopenia—Docetaxel—skin cancer	0.000465	0.00188	CcSEcCtD
Mianserin—Tachycardia—Docetaxel—skin cancer	0.000463	0.00187	CcSEcCtD
Mianserin—Skin disorder—Docetaxel—skin cancer	0.000461	0.00186	CcSEcCtD
Mianserin—Rash—Temozolomide—skin cancer	0.00045	0.00182	CcSEcCtD
Mianserin—CYP3A4—female reproductive system—skin cancer	0.00045	0.00516	CbGeAlD
Mianserin—Dermatitis—Temozolomide—skin cancer	0.00045	0.00182	CcSEcCtD
Mianserin—Headache—Temozolomide—skin cancer	0.000447	0.00181	CcSEcCtD
Mianserin—Hypotension—Docetaxel—skin cancer	0.000444	0.00179	CcSEcCtD
Mianserin—CYP2D6—female reproductive system—skin cancer	0.000443	0.00507	CbGeAlD
Mianserin—Dizziness—Fluorouracil—skin cancer	0.000435	0.00176	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000432	0.00175	CcSEcCtD
Mianserin—Paraesthesia—Docetaxel—skin cancer	0.000426	0.00172	CcSEcCtD
Mianserin—Somnolence—Docetaxel—skin cancer	0.000422	0.0017	CcSEcCtD
Mianserin—ADRA2C—lymph node—skin cancer	0.000419	0.0048	CbGeAlD
Mianserin—Rash—Fluorouracil—skin cancer	0.000415	0.00167	CcSEcCtD
Mianserin—Dermatitis—Fluorouracil—skin cancer	0.000414	0.00167	CcSEcCtD
Mianserin—Headache—Fluorouracil—skin cancer	0.000412	0.00166	CcSEcCtD
Mianserin—Gastrointestinal disorder—Docetaxel—skin cancer	0.00041	0.00165	CcSEcCtD
Mianserin—Fatigue—Docetaxel—skin cancer	0.000409	0.00165	CcSEcCtD
Mianserin—Constipation—Docetaxel—skin cancer	0.000406	0.00164	CcSEcCtD
Mianserin—HTR2A—head—skin cancer	0.000406	0.00465	CbGeAlD
Mianserin—Feeling abnormal—Docetaxel—skin cancer	0.000391	0.00158	CcSEcCtD
Mianserin—CYP2D6—head—skin cancer	0.00037	0.00424	CbGeAlD
Mianserin—Asthenia—Docetaxel—skin cancer	0.000341	0.00138	CcSEcCtD
Mianserin—HRH1—lymph node—skin cancer	0.00034	0.0039	CbGeAlD
Mianserin—Pruritus—Docetaxel—skin cancer	0.000336	0.00136	CcSEcCtD
Mianserin—ADRA2A—lymph node—skin cancer	0.000334	0.00383	CbGeAlD
Mianserin—Dizziness—Docetaxel—skin cancer	0.000314	0.00127	CcSEcCtD
Mianserin—Rash—Docetaxel—skin cancer	0.000299	0.00121	CcSEcCtD
Mianserin—Dermatitis—Docetaxel—skin cancer	0.000299	0.00121	CcSEcCtD
Mianserin—Headache—Docetaxel—skin cancer	0.000297	0.0012	CcSEcCtD
Mianserin—HTR2C—Signaling Pathways—SMO—skin cancer	2.96e-05	0.000384	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—ENO2—skin cancer	2.95e-05	0.000382	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—FOXO4—skin cancer	2.93e-05	0.00038	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—PTGER4—skin cancer	2.9e-05	0.000375	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—PTGER4—skin cancer	2.88e-05	0.000373	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—SMO—skin cancer	2.88e-05	0.000373	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PTCH1—skin cancer	2.88e-05	0.000373	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—BRAF—skin cancer	2.84e-05	0.000368	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—CSPG4—skin cancer	2.83e-05	0.000367	CbGpPWpGaD
Mianserin—HRH4—Signaling by GPCR—KRAS—skin cancer	2.81e-05	0.000365	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PTGER4—skin cancer	2.8e-05	0.000363	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—ENO2—skin cancer	2.76e-05	0.000358	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—SHH—skin cancer	2.75e-05	0.000357	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—RASA1—skin cancer	2.74e-05	0.000355	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—SHH—skin cancer	2.71e-05	0.000351	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—SHH—skin cancer	2.7e-05	0.000351	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—RASA1—skin cancer	2.69e-05	0.000349	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—RASA1—skin cancer	2.69e-05	0.000348	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—FOXO4—skin cancer	2.65e-05	0.000343	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—SMO—skin cancer	2.61e-05	0.000339	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PTCH1—skin cancer	2.61e-05	0.000339	CbGpPWpGaD
Mianserin—ADRA2B—Hemostasis—NRAS—skin cancer	2.6e-05	0.000337	CbGpPWpGaD
Mianserin—HTR1F—Signaling by GPCR—KRAS—skin cancer	2.6e-05	0.000337	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—SMO—skin cancer	2.57e-05	0.000333	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PTCH1—skin cancer	2.57e-05	0.000333	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PTCH1—skin cancer	2.56e-05	0.000332	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—SMO—skin cancer	2.56e-05	0.000332	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—FOXO4—skin cancer	2.56e-05	0.000332	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—FOXO4—skin cancer	2.54e-05	0.00033	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PTGER4—skin cancer	2.54e-05	0.00033	CbGpPWpGaD
Mianserin—HRH2—Signaling by GPCR—NRAS—skin cancer	2.54e-05	0.000329	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PTGER4—skin cancer	2.5e-05	0.000324	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PTGER4—skin cancer	2.5e-05	0.000324	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—FOXO4—skin cancer	2.47e-05	0.000321	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—SHH—skin cancer	2.47e-05	0.00032	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—RASA1—skin cancer	2.45e-05	0.000318	CbGpPWpGaD
Mianserin—ADRA2C—Hemostasis—NRAS—skin cancer	2.43e-05	0.000315	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—CSPG4—skin cancer	2.4e-05	0.00031	CbGpPWpGaD
Mianserin—HRH4—Signaling by GPCR—HRAS—skin cancer	2.39e-05	0.00031	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—BRAF—skin cancer	2.38e-05	0.000309	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—TERT—skin cancer	2.34e-05	0.000304	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—SMO—skin cancer	2.34e-05	0.000303	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PTCH1—skin cancer	2.34e-05	0.000303	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—TERT—skin cancer	2.31e-05	0.000299	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—TERT—skin cancer	2.31e-05	0.000299	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PLIN2—skin cancer	2.29e-05	0.000297	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—TERT—skin cancer	2.29e-05	0.000297	CbGpPWpGaD
Mianserin—HRH4—Signaling by GPCR—IL6—skin cancer	2.29e-05	0.000297	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PTGER4—skin cancer	2.28e-05	0.000295	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—FOXO4—skin cancer	2.25e-05	0.000291	CbGpPWpGaD
Mianserin—ADRA2B—Hemostasis—KRAS—skin cancer	2.24e-05	0.00029	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—FOXO4—skin cancer	2.21e-05	0.000286	CbGpPWpGaD
Mianserin—HTR1F—Signaling by GPCR—HRAS—skin cancer	2.21e-05	0.000286	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—FOXO4—skin cancer	2.2e-05	0.000286	CbGpPWpGaD
Mianserin—HRH2—Signaling by GPCR—KRAS—skin cancer	2.18e-05	0.000283	CbGpPWpGaD
Mianserin—HTR1F—Signaling by GPCR—IL6—skin cancer	2.11e-05	0.000274	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—ERCC2—skin cancer	2.11e-05	0.000273	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—TERT—skin cancer	2.11e-05	0.000273	CbGpPWpGaD
Mianserin—ADRA2C—Hemostasis—KRAS—skin cancer	2.09e-05	0.000271	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—FOXO4—skin cancer	2.01e-05	0.000261	CbGpPWpGaD
Mianserin—ADRA2B—Hemostasis—TP53—skin cancer	1.99e-05	0.000258	CbGpPWpGaD
Mianserin—OPRK1—Signaling by GPCR—NRAS—skin cancer	1.97e-05	0.000256	CbGpPWpGaD
Mianserin—ADRA2A—Hemostasis—NRAS—skin cancer	1.97e-05	0.000256	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—TERT—skin cancer	1.96e-05	0.000254	CbGpPWpGaD
Mianserin—HTR6—Signaling by GPCR—NRAS—skin cancer	1.94e-05	0.000252	CbGpPWpGaD
Mianserin—HTR7—Signaling by GPCR—NRAS—skin cancer	1.94e-05	0.000252	CbGpPWpGaD
Mianserin—HRH4—Signaling Pathways—NRAS—skin cancer	1.93e-05	0.00025	CbGpPWpGaD
Mianserin—HTR1D—Signaling by GPCR—NRAS—skin cancer	1.93e-05	0.00025	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—ENO2—skin cancer	1.92e-05	0.000249	CbGpPWpGaD
Mianserin—ADRA2B—Hemostasis—HRAS—skin cancer	1.9e-05	0.000246	CbGpPWpGaD
Mianserin—ADRA2C—Hemostasis—TP53—skin cancer	1.86e-05	0.000241	CbGpPWpGaD
Mianserin—HRH2—Signaling by GPCR—HRAS—skin cancer	1.85e-05	0.00024	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—BRAF—skin cancer	1.85e-05	0.00024	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—CSPG4—skin cancer	1.85e-05	0.00024	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—BRAF—skin cancer	1.83e-05	0.000237	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—BRAF—skin cancer	1.83e-05	0.000237	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—BRAF—skin cancer	1.81e-05	0.000235	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—NRAS—skin cancer	1.78e-05	0.000231	CbGpPWpGaD
Mianserin—ADRA2C—Hemostasis—HRAS—skin cancer	1.78e-05	0.00023	CbGpPWpGaD
Mianserin—HRH2—Signaling by GPCR—IL6—skin cancer	1.78e-05	0.00023	CbGpPWpGaD
Mianserin—HTR2B—Signaling by GPCR—NRAS—skin cancer	1.77e-05	0.00023	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—TERT—skin cancer	1.77e-05	0.000229	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—ERCC2—skin cancer	1.71e-05	0.000222	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—TERT—skin cancer	1.71e-05	0.000221	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—TERT—skin cancer	1.7e-05	0.00022	CbGpPWpGaD
Mianserin—OPRK1—Signaling by GPCR—KRAS—skin cancer	1.7e-05	0.00022	CbGpPWpGaD
Mianserin—ADRA2A—Hemostasis—KRAS—skin cancer	1.7e-05	0.00022	CbGpPWpGaD
Mianserin—HTR6—Signaling by GPCR—KRAS—skin cancer	1.67e-05	0.000217	CbGpPWpGaD
Mianserin—HTR7—Signaling by GPCR—KRAS—skin cancer	1.67e-05	0.000217	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—BRAF—skin cancer	1.67e-05	0.000216	CbGpPWpGaD
Mianserin—HRH4—Signaling Pathways—KRAS—skin cancer	1.66e-05	0.000216	CbGpPWpGaD
Mianserin—HTR1D—Signaling by GPCR—KRAS—skin cancer	1.66e-05	0.000215	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—TERT—skin cancer	1.65e-05	0.000214	CbGpPWpGaD
Mianserin—DRD3—Signaling by GPCR—NRAS—skin cancer	1.65e-05	0.000214	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—ENO2—skin cancer	1.63e-05	0.000211	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—ERCC2—skin cancer	1.61e-05	0.000208	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—BRAF—skin cancer	1.55e-05	0.000201	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—KRAS—skin cancer	1.53e-05	0.000199	CbGpPWpGaD
Mianserin—HTR2B—Signaling by GPCR—KRAS—skin cancer	1.53e-05	0.000198	CbGpPWpGaD
Mianserin—ADRA2A—Hemostasis—TP53—skin cancer	1.51e-05	0.000195	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—TERT—skin cancer	1.5e-05	0.000194	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—NRAS—skin cancer	1.5e-05	0.000194	CbGpPWpGaD
Mianserin—ADRA2B—Signaling by GPCR—NRAS—skin cancer	1.49e-05	0.000193	CbGpPWpGaD
Mianserin—HRH4—Signaling Pathways—TP53—skin cancer	1.48e-05	0.000192	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—TERT—skin cancer	1.48e-05	0.000191	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—TERT—skin cancer	1.47e-05	0.000191	CbGpPWpGaD
Mianserin—OPRK1—Signaling by GPCR—HRAS—skin cancer	1.44e-05	0.000187	CbGpPWpGaD
Mianserin—ADRA2A—Hemostasis—HRAS—skin cancer	1.44e-05	0.000187	CbGpPWpGaD
Mianserin—HTR1A—Signaling by GPCR—NRAS—skin cancer	1.44e-05	0.000187	CbGpPWpGaD
Mianserin—HTR2C—Signaling by GPCR—NRAS—skin cancer	1.43e-05	0.000186	CbGpPWpGaD
Mianserin—HTR6—Signaling by GPCR—HRAS—skin cancer	1.42e-05	0.000184	CbGpPWpGaD
Mianserin—DRD3—Signaling by GPCR—KRAS—skin cancer	1.42e-05	0.000184	CbGpPWpGaD
Mianserin—HTR7—Signaling by GPCR—HRAS—skin cancer	1.42e-05	0.000184	CbGpPWpGaD
Mianserin—HRH4—Signaling Pathways—HRAS—skin cancer	1.41e-05	0.000183	CbGpPWpGaD
Mianserin—HTR1D—Signaling by GPCR—HRAS—skin cancer	1.41e-05	0.000183	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—BRAF—skin cancer	1.4e-05	0.000182	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—NRAS—skin cancer	1.39e-05	0.000181	CbGpPWpGaD
Mianserin—OPRK1—Signaling by GPCR—IL6—skin cancer	1.38e-05	0.000179	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—TP53—skin cancer	1.36e-05	0.000177	CbGpPWpGaD
Mianserin—HTR6—Signaling by GPCR—IL6—skin cancer	1.36e-05	0.000177	CbGpPWpGaD
Mianserin—HTR7—Signaling by GPCR—IL6—skin cancer	1.36e-05	0.000176	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—BRAF—skin cancer	1.35e-05	0.000175	CbGpPWpGaD
Mianserin—HRH4—Signaling Pathways—IL6—skin cancer	1.35e-05	0.000175	CbGpPWpGaD
Mianserin—HTR1D—Signaling by GPCR—IL6—skin cancer	1.35e-05	0.000175	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—BRAF—skin cancer	1.35e-05	0.000174	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—TERT—skin cancer	1.34e-05	0.000174	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—BRAF—skin cancer	1.31e-05	0.00017	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—HRAS—skin cancer	1.3e-05	0.000169	CbGpPWpGaD
Mianserin—HTR2B—Signaling by GPCR—HRAS—skin cancer	1.3e-05	0.000168	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—KRAS—skin cancer	1.29e-05	0.000167	CbGpPWpGaD
Mianserin—ADRA2B—Signaling by GPCR—KRAS—skin cancer	1.28e-05	0.000166	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.27e-05	0.000165	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—PTGS2—skin cancer	1.26e-05	0.000164	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—NRAS—skin cancer	1.26e-05	0.000164	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ENO2—skin cancer	1.26e-05	0.000163	CbGpPWpGaD
Mianserin—HTR1F—Signaling Pathways—IL6—skin cancer	1.25e-05	0.000162	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—NRAS—skin cancer	1.24e-05	0.000161	CbGpPWpGaD
Mianserin—HTR2B—Signaling by GPCR—IL6—skin cancer	1.24e-05	0.000161	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—NRAS—skin cancer	1.24e-05	0.000161	CbGpPWpGaD
Mianserin—HTR1A—Signaling by GPCR—KRAS—skin cancer	1.24e-05	0.000161	CbGpPWpGaD
Mianserin—HTR2C—Signaling by GPCR—KRAS—skin cancer	1.23e-05	0.00016	CbGpPWpGaD
Mianserin—DRD3—Signaling by GPCR—HRAS—skin cancer	1.21e-05	0.000157	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—KRAS—skin cancer	1.2e-05	0.000155	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—BRAF—skin cancer	1.19e-05	0.000154	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—BRAF—skin cancer	1.17e-05	0.000152	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—BRAF—skin cancer	1.17e-05	0.000151	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—NRAS—skin cancer	1.17e-05	0.000151	CbGpPWpGaD
Mianserin—DRD3—Signaling by GPCR—IL6—skin cancer	1.16e-05	0.00015	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—NRAS—skin cancer	1.15e-05	0.000149	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—NRAS—skin cancer	1.15e-05	0.000149	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—TP53—skin cancer	1.15e-05	0.000149	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—NRAS—skin cancer	1.14e-05	0.000148	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—NRAS—skin cancer	1.13e-05	0.000147	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—ERCC2—skin cancer	1.12e-05	0.000145	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—HRAS—skin cancer	1.1e-05	0.000142	CbGpPWpGaD
Mianserin—ADRA2B—Signaling by GPCR—HRAS—skin cancer	1.09e-05	0.000141	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—KRAS—skin cancer	1.09e-05	0.000141	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—KRAS—skin cancer	1.07e-05	0.000139	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—KRAS—skin cancer	1.07e-05	0.000138	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—BRAF—skin cancer	1.06e-05	0.000138	CbGpPWpGaD
Mianserin—HTR1A—Signaling by GPCR—HRAS—skin cancer	1.05e-05	0.000137	CbGpPWpGaD
Mianserin—HRH2—Signaling Pathways—IL6—skin cancer	1.05e-05	0.000136	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—NRAS—skin cancer	1.05e-05	0.000136	CbGpPWpGaD
Mianserin—HTR2C—Signaling by GPCR—HRAS—skin cancer	1.05e-05	0.000136	CbGpPWpGaD
Mianserin—ADRA2B—Signaling by GPCR—IL6—skin cancer	1.04e-05	0.000135	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PTGS2—skin cancer	1.03e-05	0.000133	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—HRAS—skin cancer	1.02e-05	0.000132	CbGpPWpGaD
Mianserin—HTR1A—Signaling by GPCR—IL6—skin cancer	1.01e-05	0.000131	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—KRAS—skin cancer	1e-05	0.00013	CbGpPWpGaD
Mianserin—HTR2C—Signaling by GPCR—IL6—skin cancer	1e-05	0.00013	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—KRAS—skin cancer	9.89e-06	0.000128	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—KRAS—skin cancer	9.88e-06	0.000128	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—KRAS—skin cancer	9.81e-06	0.000127	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—NRAS—skin cancer	9.76e-06	0.000126	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—IL6—skin cancer	9.75e-06	0.000126	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—KRAS—skin cancer	9.74e-06	0.000126	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PTGS2—skin cancer	9.63e-06	0.000125	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—ERCC2—skin cancer	9.46e-06	0.000123	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—HRAS—skin cancer	9.25e-06	0.00012	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—HRAS—skin cancer	9.1e-06	0.000118	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—HRAS—skin cancer	9.08e-06	0.000118	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—KRAS—skin cancer	9.02e-06	0.000117	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—TP53—skin cancer	8.92e-06	0.000116	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—IL6—skin cancer	8.85e-06	0.000115	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—NRAS—skin cancer	8.81e-06	0.000114	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—TP53—skin cancer	8.79e-06	0.000114	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—TP53—skin cancer	8.78e-06	0.000114	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—TP53—skin cancer	8.72e-06	0.000113	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—IL6—skin cancer	8.71e-06	0.000113	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—IL6—skin cancer	8.69e-06	0.000113	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—HRAS—skin cancer	8.53e-06	0.000111	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—NRAS—skin cancer	8.5e-06	0.00011	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—NRAS—skin cancer	8.46e-06	0.00011	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—HRAS—skin cancer	8.4e-06	0.000109	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—KRAS—skin cancer	8.4e-06	0.000109	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—HRAS—skin cancer	8.39e-06	0.000109	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—HRAS—skin cancer	8.34e-06	0.000108	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—HRAS—skin cancer	8.28e-06	0.000107	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—NRAS—skin cancer	8.23e-06	0.000107	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—IL6—skin cancer	8.16e-06	0.000106	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—IL6—skin cancer	8.04e-06	0.000104	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—IL6—skin cancer	8.03e-06	0.000104	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—TP53—skin cancer	8.02e-06	0.000104	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—IL6—skin cancer	7.98e-06	0.000103	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—IL6—skin cancer	7.92e-06	0.000103	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—HRAS—skin cancer	7.67e-06	9.94e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—KRAS—skin cancer	7.58e-06	9.83e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—NRAS—skin cancer	7.47e-06	9.68e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—TP53—skin cancer	7.46e-06	9.68e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—NRAS—skin cancer	7.35e-06	9.52e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—IL6—skin cancer	7.34e-06	9.52e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—NRAS—skin cancer	7.33e-06	9.5e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—KRAS—skin cancer	7.32e-06	9.49e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ERCC2—skin cancer	7.3e-06	9.46e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—KRAS—skin cancer	7.28e-06	9.44e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—HRAS—skin cancer	7.14e-06	9.25e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—KRAS—skin cancer	7.08e-06	9.18e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—IL6—skin cancer	6.83e-06	8.86e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—TP53—skin cancer	6.74e-06	8.73e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTGS2—skin cancer	6.69e-06	8.68e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—NRAS—skin cancer	6.68e-06	8.66e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—TP53—skin cancer	6.5e-06	8.43e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—TP53—skin cancer	6.47e-06	8.39e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—HRAS—skin cancer	6.44e-06	8.35e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—KRAS—skin cancer	6.43e-06	8.33e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—KRAS—skin cancer	6.32e-06	8.2e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—KRAS—skin cancer	6.31e-06	8.18e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—TP53—skin cancer	6.29e-06	8.16e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—HRAS—skin cancer	6.22e-06	8.06e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—HRAS—skin cancer	6.19e-06	8.02e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—IL6—skin cancer	6.17e-06	8e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—HRAS—skin cancer	6.02e-06	7.8e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—IL6—skin cancer	5.95e-06	7.72e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—IL6—skin cancer	5.92e-06	7.68e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—IL6—skin cancer	5.76e-06	7.47e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—KRAS—skin cancer	5.75e-06	7.46e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—TP53—skin cancer	5.71e-06	7.4e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTGS2—skin cancer	5.67e-06	7.35e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—TP53—skin cancer	5.62e-06	7.28e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—TP53—skin cancer	5.61e-06	7.27e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—HRAS—skin cancer	5.46e-06	7.08e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—HRAS—skin cancer	5.37e-06	6.97e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—HRAS—skin cancer	5.36e-06	6.95e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IL6—skin cancer	5.23e-06	6.78e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IL6—skin cancer	5.14e-06	6.67e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IL6—skin cancer	5.13e-06	6.65e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—TP53—skin cancer	5.11e-06	6.63e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—HRAS—skin cancer	4.89e-06	6.34e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IL6—skin cancer	4.68e-06	6.07e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTGS2—skin cancer	4.38e-06	5.67e-05	CbGpPWpGaD
